Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C84.6C88.0-Z94.80MeSHHodgkin DiseaseLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellTransplantation, AutologousSequenceChemotherapyChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaNo. Substances46 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimNo. Substances46Protocol classificationTherapy classificationalternativecurrent standardIntensityHigh dose myeloablativeStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseconditioningSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityInfectionsMucositisOral MucositisPyrexia only studiesPublicationAuthorCaballero MDKirschey SLadetto MVisani GDiseaseFollikuläres Lymphom °I-IIIa, ECOG 0-2NHL, HL, Rezidiv, fehlende Remission nach kurativer Chemotherapierefraktäres oder rezidivierendes NHL oder HL, Rituximab Vortherapierezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2OriginDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, Hospital Universitario Salamanca, SpanienDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy; FLAZ-12Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, ItalyProtocols in Revision 4 protocols foundProtocols under revision.BEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation, Autologous (PID280 V2.1)BeEAM - Bendamustine 100 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation (PID879 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)TEAM - Thiotepa 5 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to Stem Cell Transplantation, Autologous (PID406 V2.0)
